close
ASIAN (B)

GV20 Oncotherapy Completes Series B Financing to Advance Pipeline into the Clinic and Expand Immuno-Oncology Drug Discovery Platform

GV20.jpg



Intellasia East Asia News

SHANGHAI, Oct. 14, 2021 /PRNewswire/ — GV20 Oncotherapy, a biotechnology company with unique expertise in novel target identification and antibody drug discovery in immuno-oncology, today announced the completion of i…



Source link

The author

Leave a Response